**Appendix Table D19. Migraine prevention with topiramate vs. placebo in adults (pooled results from randomized controlled clinical trials)**

| **Outcome** | **Author, Year** | **Events/****Randomized** | **Events/****Randomized** | **Relative Risk (95% CI)** | **Weight****Random Effects****Inverse Variance** | **Absolute Risk Difference,****(95% CI)** | **Weight, Random Effects****Inverse Variance** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Frequency:≥50% reduction | Storey, 200118 | 5/19 | 2/21 | 2.8(0.6 to 12.6) | 3.34 | 0.17(-0.07 to 0.40) | 11 |
| Frequency:≥50% reduction | Mei, 200424 | 37/58 | 12/57 | 3.0(1.8 to 5.2) | 15.25 | 0.43(0.27 to 0.59) | 14.67 |
| Frequency:≥50% reduction | Bussone, 200525 | 188/386 | 93/372 | 1.9(1.6 to 2.4) | 27.28 | 0.24(0.17 to 0.30) | 19.77 |
| Frequency:≥50% reduction | Silberstein, 200629 | 55/140 | 25/73 | 1.1(0.8 to 1.7) | 20.61 | 0.05(-0.09 to 0.19) | 16.2 |
| Frequency:≥50% reduction | Silberstein, 200731 | 58/112 | 8/36 | 2.3(1.2 to 4.4) | 12.66 | 0.30(0.13 to 0.46) | 14.58 |
| Frequency:≥50% reduction | Silvestrini, 200320 | 10/14 | 1/14 | 10.0(1.5 to 68.0) | 2.18 | 0.64(0.37 to 0.92) | 9.41 |
| Frequency:≥50% reduction | Gupta, 200744 | 38/60 | 18/60 | 2.1(1.4 to 3.3) | 18.69 | 0.33(0.17 to 0.50) | 14.36 |
| **Frequency:≥50% reduction** | **Pooled** | **391/789** | **159/633** | **2.0****(1.5 to 2.7)** | **100** | **0.29****(0.18 to 0.40)** | **100** |
| Reduction in headache days by ≥50% | Bussone, 200525 | 175/386 | 81/372 | 2.1(1.7 to 2.6) | 50.32 | 0.24(0.17 to 0.30) | 41.85 |
| Reduction in headache days by ≥50% | Diener, 200734 | 7/32 | 0/27 | 12.7(0.8 to 213.1) | 3.07 | 0.22(0.07 to 0.37) | 24.44 |
| Reduction in headache days by ≥50% | Silberstein, 200941 | 64/165 | 50/163 | 1.3(0.9 to 1.7) | 46.61 | 0.08(-0.02 to 0.18) | 33.71 |
| **Reduction in headache days by ≥50%** | **Pooled** | 246/583 | 131/562 | **1.7****(1.0 to 2.9)** | **100** | **0.18****(0.08 to 0.28)** | **100** |
| Reduction in headache days by ≥75% | Bussone, 200525 | 98/386 | 41/372 | 2.3(1.6 to 3.2) | 60.07 | 0.14(0.09 to 0.20) | 52.98 |
| Reduction in headache days by ≥75% | Silberstein, 200941 | 25/165 | 18/163 | 1.4(0.8 to 2.4) | 39.93 | 0.04(-0.03 to 0.11) | 47.02 |
| **Reduction in headache days by ≥75%** | **Pooled** | **123/551** | **59/535** | **1.9****(1.1 to 3.1)** | **100** | **0.10****(-0.01 to 0.20)** | **100** |
| Outcome | Heterogeneity statistics | Degree of freedom | P valueRelative risk | I squaredRelative risk |  | P valueAbsolute risk difference | I squaredAbsolute riskdifference |
| Frequency:≥50% reduction |  | 6 | 0.036 | 55.50% |  | 0.001 | 73.60% |
| Reduction in headache days by ≥50% |  | 2 | 0.012 | 77.20% |  | 0.042 | 68.40% |
| Reduction in headache days by ≥75% |  | 1 | 0.123 | 58.00% |  | 0.026 | 79.70% |

Bold = significant at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0

CI = confidence interval